Literature DB >> 21707691

Similar superantigen gene profiles and superantigen activity in norwegian isolates of invasive and non-invasive group a streptococci.

T E Michaelsen1, I K G Andreasson, B K Langerud, D A Caugant.   

Abstract

Group A streptococcus (GAS) harbours several virulence factors, including M protein (coded by the emm gene) and superantigens (SAgs). SAgs are extracellular toxins that directly activate the immune system by cross-binding to the HLA class II molecule and T cell receptor (TCR), thereby causing activation of up to 30% of the T cells and subsequent massive secretion of cytokines. Forty-eight GAS strains isolated from patients at Norwegian hospitals between 1988 and 2004 were included in this study. Of these, 24 were invasive streptococcal toxic shock syndrome (STSS) or necrotizing fasciitis (NF) isolates and 24 were non-invasive pharyngitis isolates, matched for having the same T-type and year of isolation as the invasive isolates. The isolates were characterized by emm sequence typing, multilocus sequence typing (MLST) and SAg gene profiles. A correlation between T-type, emm type, sequence type and SAg gene profile was revealed. No difference between invasive and non-invasive isolates regarding serotype or genotype was demonstrated. Selected invasive and non-invasive isolates with identical SAg gene profiles were analysed for SAg activity in bacterial growth culture media with and without human cell culture media added. A human T cell proliferation assay was used as measurement for SAg activity and simultaneously we also measured the cytokine content in normal human peripheral blood leucocyte cell culture media. The results revealed that invasive and non-invasive isolates did not differ significantly in SAg activity as it is present in semipurified bacterial culture medium.
© 2011 The Authors. Scandinavian Journal of Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707691     DOI: 10.1111/j.1365-3083.2011.02594.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

Review 1.  Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

Authors:  Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

2.  Streptococcus pyogenes strains associated with invasive and non-invasive infections present possible links with emm types and superantigens.

Authors:  Rao Muhammad Abid Khan; Sana Anwar; Zaid Ahmed Pirzada
Journal:  Iran J Basic Med Sci       Date:  2020-01       Impact factor: 2.699

3.  Streptococcus pyogenes strains in Sao Paulo, Brazil: molecular characterization as a basis for StreptInCor coverage capacity analysis.

Authors:  Samar Freschi de Barros; Karine Marafigo De Amicis; Raquel Alencar; Pierre Robert Smeesters; Ariel Trunkel; Edilberto Postól; João Nóbrega Almeida Junior; Flavia Rossi; Antonio Carlos Campos Pignatari; Jorge Kalil; Luiza Guilherme
Journal:  BMC Infect Dis       Date:  2015-08-05       Impact factor: 3.090

Review 4.  The contribution of group A streptococcal virulence determinants to the pathogenesis of sepsis.

Authors:  Mark Reglinski; Shiranee Sriskandan
Journal:  Virulence       Date:  2013-10-09       Impact factor: 5.882

5.  Distribution of superantigens in group A streptococcal isolates from Salvador, Brazil.

Authors:  Hillary F Berman; Sara Yee Tartof; Joice N Reis; Mitermayer G Reis; Lee W Riley
Journal:  BMC Infect Dis       Date:  2014-05-29       Impact factor: 3.090

6.  Genomic Comparison among Lethal Invasive Strains of Streptococcus pyogenes Serotype M1.

Authors:  Gabriel R Fernandes; Aulus E A D Barbosa; Renan N Almeida; Fabíola F Dos S Castro; Marina de C P da Ponte; Celio Faria-Junior; Fernanda M P Müller; Antônio A B Viana; Dario Grattapaglia; Octavio L Franco; Sérgio A Alencar; Simoni C Dias
Journal:  Front Microbiol       Date:  2017-10-23       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.